

OFFICE OF BIOTECHNOLOGY AND BUSINESS DEVELOPMENT

OPPORTUNITIES FOR INDUSTRY COLLABORATION AND SPONSORED RESEARCH

We strongly advise that you engage the Office of Biotechnology and Business Development before you submit. This is to ensure that you **ONLY** disclose **NON-CONFIDENTIAL INFORMATION**, otherwise it might jeopardize future intellectual property (IP) protection. For more information regarding application format, submission, contact Nilam Sinha, Ph.D. (Marketing Manager) at the Office of Biotechnology and Business Development. E-mail: nilam.sinha@einsteinmed.edu; Tel: 718.430.3421

Just launched

Novel Strategies for Targeted Drug Delivery to CNS, Bone, Cartilage, Skeletal Muscle and Kidney Tissues

Company:

Requested anonymity

Brief:

A global leader in the creation and commercialization of pioneering therapies, is looking for novel strategies for tissue-specific drug delivery to central nervous system (CNS), bone, connective tissue/cartilage, skeletal muscle, and kidney tissues.



Submission deadline: 30th September 2024

→ [Download PDF](#)


Seeking Transformational Therapeutic Approaches for Sickle Cell Disease and Beta-thalassemia

Company:

Requested anonymity

Brief:

A leading company in rare genetic disease is seeking disease modifying therapeutic approaches for sickle cell disease (SCD) and beta-thalassemia, addressing fetal globin levels, beta-globin levels or vaso-occlusive crisis.



Submission deadline: 30th September 2024

→ [Download PDF](#)

Closing soon


Novel Approaches for the Delivery of Viable and Healthy Cells for Cell Therapy Treatment

Company:

Novo Nordisk

Brief:

Novo Nordisk is seeking novel cell delivery solutions to improve cell therapy treatments for type 1 diabetes, chronic heart failure and Parkinson's disease.



Submission deadline: 12th August 2024

→ [Download PDF](#)

Ongoing campaign

Novel Oral Therapeutics for the Treatment of Immunology and Inflammation Diseases

Company:

Requested anonymity

Brief:

A multinational pharmaceutical company is seeking novel oral therapeutics that act on clinically validated targets for immunology and inflammation diseases.



Submission deadline: 16th September 2024

→ [Download PDF](#)

Seeking Novel Solutions to Treat Rare Genetic Skeletal Muscle Diseases

Company:

Requested anonymity

Brief:

A world-leading company in rare genetic diseases is looking for novel approaches to target the primary cause of rare genetic skeletal muscle diseases.



Submission deadline: 23rd September 2024

→ [Download PDF](#)

Accessible and Transformational Therapeutic Approaches for Hereditary Haemorrhagic Telangiectasia (HHT)

Company:

Requested anonymity

Brief:

A world leader in therapies for rare genetic diseases, is seeking novel disease modifying therapeutic approaches for hereditary haemorrhagic telangiectasia (HHT) type 1 and type 2.



Submission deadline: 23rd September 2024

→ [Download PDF](#)

Have questions?

Learn more about Connect campaigns and the submissions process at our [FAQ pages](#) or contact our team directly at discover@in-part.co.uk.

Inpart, 89 rue Tronchet, 69006, Lyon, Auvergne-Rhône-Alpes, France
© 2024 Inpart. All rights reserved unless otherwise agreed.
[Update your email preferences or unsubscribe from this list.](#)